AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02586311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-330 16/5mg Placebo
Description: Once a day, 8 weeks
Study NCT02586311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5mg
Description: Once a day, 8 weeks
Study NCT00929487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens multi-purpose solution
Description: Lens care solutions CE-marked for intended use. A fresh pair of contact lenses was soaked overnight in the test contact lens solution and a pre-cycled lens case prior to study visit, then worn for two hours on the day of the study visit. Up to four solutions were evaluated in randomized order with the same brand of contact lenses, and a minimum of 12 hours of no lens wear separated each wear period.
Study NCT00929487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline/blister pack solution
Description: A fresh pair of contact lenses was soaked overnight in saline prior to study visit or was inserted directly from the blister pack, then worn for two hours on the day of the study visit.
Study NCT00929487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lenses
Description: CE-marked silicone hydrogel contact lenses soaked overnight for at least 10 hours prior to the study visit, then worn for two hours on the day of the study visit. A fresh pair of the same brand of contact lenses was used for each overnight soak (ie, 4 solutions plus saline/blister pack solution), and a minimum of 12 hours separated each wear period.
Study NCT00929487 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lenses
Description: CE-marked silicone hydrogel contact lenses soaked overnight for at least 10 hours prior to the study visit, then worn for two hours on the day of the study visit. A fresh pair of the same brand of contact lenses was used for each overnight soak (ie, 4 solutions plus saline/blister pack solution), and a minimum of 12 hours separated each wear period.
Study NCT02710487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REMSA
Description: Awakening from REM sleep during the last hour of the sleep period
Study NCT02710487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NREMSA
Description: Awakening from N2 (NREM) sleep during the last hour of the sleep period
Study NCT01205880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol ointment
Description: twice daily
Study NCT01205880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol spray
Description: twice daily
Study NCT02541955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acthar
Description: Injections will be self administered
Study NCT00168428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Two treatment sessions in the double-blind phase and three treatment sessions in the open-label phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
Study NCT00168428 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo (saline)
Description: Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
Study NCT04301739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
Study NCT04301739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide
Description: chemotherapeutics
Study NCT04301739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide
Description: chemotherapeutics
Study NCT04301739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04256564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central venous catheterization
Description: A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance
Study NCT02861664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous fluoride (SnF2)
Description: Dentifrice containing 0.454% weight by weight (w/w) SnF2 and 0.072% w/w NaF
Study NCT02861664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate (SMFP)
Description: Dentifrice containing 1400 ppm fluoride as SMFP
Study NCT01268657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Learning about anxiety
Study NCT01268657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Training
Description: Learning skills to reduce tension
Study NCT01268657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: Learning skills needed to cope better with distressing thoughts
Study NCT01268657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Learning to initiate healthy activity
Study NCT01268657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: Coaching in how to confront avoided thoughts, situations, and people)
Study NCT04219592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IgG4 measurement (non-interventional, just obtaining data from medical records)
Description: IgG4 measurement in mg/dL
Study NCT02063594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCTX (PEGylated Liposomal Iodixanol Injection)
Description: Single dose of NCTX (PEGylated Liposomal Iodixanol Injection) administered at escalating doses from 9 mg I/kg up to 110 mg I/kg
Study NCT02063594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Single dose of 0.9% Sodium Chloride Injection, USP administered similarly and at an equivalent dose volume as the active drug
Study NCT04323384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotene® Oralbalance Moisturizing Gel
Description: Biotene® Oralbalance Moisturizing Gel will be applied to the oral cavity according to the package directions.
Study NCT02603211 — intervention group
Intervention type: DEVICE
Intervention: tactile imaging sensor or system made in our laboratory
Description: This is a camera with elastomer tip and LED lights. It is a harmless device.
Study NCT04232644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADAIR 10mg IR capsules
Description: manipulated ADAIR IR 3x10 mg capsules
Study NCT04232644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADAIR 10mg IR capsules
Description: manipulated ADAIR IR 3x10 mg capsules
Study NCT04232644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crushed d-amphetamine sulfate IR tablets
Description: crushed d-amphetamine sulfate IR 6 x 5 mg tablets
Study NCT04232644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crushed d-amphetamine sulfate IR tablets
Description: crushed d-amphetamine sulfate IR 6 x 5 mg tablets
Study NCT03822156 — intervention group
Intervention type: OTHER
Intervention: Observation of AFB smear/culture
Description: Observation of the patients from group for their AFB smear/culture results
Study NCT03939923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Intubation with Rocuronium 1.0-1.2 mg/kg (vitals maintained within 20% of baseline. Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure.
Study NCT03939923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage)
Study NCT03939923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Reversal glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage)
Study NCT03939923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Reversal with Sugammadex (2mg/kg)
Study NCT01947842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone App Dosecast
Description: The Dosecast app is configured to remind the patient to take their medication.
Study NCT04461548 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Thinking, writing and imagining
Description: All participants are asked to take some time to think and write about the content of the respective intervention group. After the writing exercise (approx. 15-20 min) participants are asked to imagine that content for about 5 minutes.
Study NCT04461548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thinking, writing and imagining
Description: All participants are asked to take some time to think and write about the content of the respective intervention group. After the writing exercise (approx. 15-20 min) participants are asked to imagine that content for about 5 minutes.
Study NCT01301300 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Disinfecting Cap
Description: Replace standard practice with using the disinfecting cap
Study NCT02749227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use.~The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained.
Study NCT02364583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Primaquine treatment given in a step-wise manner; (a) 0.5 mg/kg total dose daily for 14 days (n=40), (b) 1.0 mg/kg total dose daily for 7 days (n=40), (c) 1.0 mg/kg twice daily for 3.5 days (n=40)
Study NCT02136901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NUsurface® Meniscus Implant
Description: The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
Study NCT02136901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID's and Non-surgical Treatment Options
Description: Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
Study NCT02136901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-Articular Injections with Corticosteroids
Description: Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
Study NCT02136901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-Articular Injections with Hyaluronic Acid (HA)
Description: Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
Study NCT01646840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242 capsule
Description: Single dose of PF-04958242 0.35 mg oral capsule
Study NCT01646840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04958242 oral solution
Description: Single dose of PF-04958242 0.35 mg oral solution
Study NCT03438084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Interesterified fat
Description: 50 g fat provided as commercially available interesterified fat.
Study NCT03438084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non- interesterified fat
Description: 50 g fat provided as commercially available non-interesterified fat.
Study NCT03438084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rapeseed oil
Description: 50 g fat provided as commercially available rapeseed oil.
Study NCT03438084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Butter
Description: 50g fat provided as commercially available spreadable butter
Study NCT02753816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT02753816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study NCT02872233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987519
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study NCT02872233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 15 Control
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study NCT01307891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane alone
Description: 100 mg/m2 weekly X 3 doses (Days 1, 8, 15) at 28-day intervals until disease progression or unacceptable toxicity. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
Study NCT01307891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane + Tigatuzumab
Description: Tigatuzumab will be administered as a loading dose of 10 mg/kg on Day 1, then 5 mg/kg on Day 15 and then every other week on Days 1 and 15 of subsequent cycles. It will be given as an IV infusion over 60 minutes or less. No dose reductions will be allowed. Tigatuzumab will be administered in combination with the Abraxane according to the intervention described for it.
Study NCT03717779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis
Study NCT00064103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5CMV-p53 gene
Description: Given intramucosally or as oral rinse
Study NCT00064103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01757860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CARD-024
Description: Comparison of different dosages of drug
Study NCT01757860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Drug Carrier
Description: Drug Carrier, 20% ethanol:80% propylene glycol oral administered solution.
Study NCT02022046 — intervention group
Intervention type: OTHER
Intervention: Methylation biosignature
Description: Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
Study NCT00160056 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hypoglycemia
Study NCT00547248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: Intramuscular injection, 1 dose
Study NCT00547248 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB
Description: Intramuscular injection, 1 dose
Study NCT00547248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB
Description: Intramuscular injection, 1 dose
Study NCT00547248 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix
Description: Reconstituted with Tritanrix-Hep B before injection
Study NCT00547248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix
Description: Reconstituted with Tritanrix-Hep B before injection
Study NCT00547248 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin
Description: Oral, 1 dose
Study NCT00547248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin
Description: Oral, 1 dose
Study NCT00547248 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Poliorix
Description: Intramuscular injection, 1 dose
Study NCT00547248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poliorix
Description: Intramuscular injection, 1 dose
Study NCT00547248 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar (Wyeth)
Description: Intramuscular injection, 1 dose
Study NCT01147718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: digoxin plus albiglutide
Description: A single dose of 0.5mg digoxin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide, followed by a single dose of 0.5mg digoxin on Day 38.
Study NCT05468983 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical ( implants placement)
Description: 4 implants were placed interforamen of the mandibular arch by using the surgical guide
Study NCT02090283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101 dermal cream (6%)
Description: SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
Study NCT02033707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hallucinogens and psychoactive substances
Description: One of the following or placebo will be given:~Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis~Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem~Antihistamines: diphenhydramine, chlorpheniramine~Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion~Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine~Other: alcohol, scopolamine, nicotine~Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects.
Study NCT03508349 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IST
Description: Women in the control group will receive routine care, which does not include testing for malaria with a rapid diagnostic test unless symptomatic for malaria. Women in the intervention group will receive this additional testing for malaria at each antenatal care, regardless of whether she is symptomatic for malaria.
Study NCT03897569 — intervention group
Intervention type: OTHER
Intervention: frontal projection angle, ankle dorsiflexion
Description: Dorsiflexion measurements will be taken in 4 different positions and repeated and recorded 3 times in each position, Prone bent, straight knee and Standing bent, straight knee. Prior to the measurement, the participants completed two 30-second calf stretches The FPPA was determined as the angle at the knee formed by lines connecting the anterior superior iliac spine, the midpoint of the femoral condyles and the midpoint of the malleoli at the deepest part of the squat
Study NCT03954002 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TTE and TOE
Description: A small flexible tube (TOE probe) will be inserted into your oesophagus, or food pipe, to take images of your heart as per routine anaesthetic care for cardiac surgery.~Just before and after general anaesthesia is administered, a short transthoracic echocardiography (TTE scan will be performed to acquire images of your heart. This is an ultrasound scan of your heart using a probe on the outside of the chest. During this period, relevant haemodynamic data such as blood pressure and heart rate will be recorded.
Study NCT03837457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobomarsen
Description: At least weekly intravenous infusions of cobomarsen (282 mg) throughout study treatment period
Study NCT01851655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plyometric Exercise
Description: Treatment sessions include a combination of running, jumping and agility activities (plyometric exercise). Each rehabilitation session will also include an abbreviated, standardized program of lower extremity strengthening (leg press, machine squats, knee extensions; 3 sets x 10 repetitions each), flexibility (standing gastrocnemius and quadriceps stretch, hamstrings stretch in long-sitting; 2 x 30 seconds each) and proprioception (standing on foam and a tilt board; 3 x 30 seconds each).
Study NCT01851655 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Plyometric Exercise
Description: Treatment sessions include a combination of running, jumping and agility activities (plyometric exercise). Each rehabilitation session will also include an abbreviated, standardized program of lower extremity strengthening (leg press, machine squats, knee extensions; 3 sets x 10 repetitions each), flexibility (standing gastrocnemius and quadriceps stretch, hamstrings stretch in long-sitting; 2 x 30 seconds each) and proprioception (standing on foam and a tilt board; 3 x 30 seconds each).